|
|
|
Rising R&D costs and shifting priorities are driving biopharma companies to use spin-offs and NewCos to advance overlooked assets. These models enable focused innovation, independent funding, and long-term value creation through sharper execution and flexible risk management. |
|
|
|
|
|
|
|
|
|
CONTRIBUTE TO LIFE SCIENCE LEADER |
|
|
|
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director. |
|
|